These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

709 related articles for article (PubMed ID: 19769391)

  • 1. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Design of next generation antibody drug conjugates].
    Zhu GD; Fu YX
    Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
    Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
    J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
    Ricart AD; Tolcher AW
    Nat Clin Pract Oncol; 2007 Apr; 4(4):245-55. PubMed ID: 17392715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues.
    Burke PJ; Senter PD; Meyer DW; Miyamoto JB; Anderson M; Toki BE; Manikumar G; Wani MC; Kroll DJ; Jeffrey SC
    Bioconjug Chem; 2009 Jun; 20(6):1242-50. PubMed ID: 19469529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance.
    Hamann PR; Hinman LM; Beyer CF; Greenberger LM; Lin C; Lindh D; Menendez AT; Wallace R; Durr FE; Upeslacis J
    Bioconjug Chem; 2005; 16(2):346-53. PubMed ID: 15769088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Linker technologies for antibody-drug conjugates.
    Nolting B
    Methods Mol Biol; 2013; 1045():71-100. PubMed ID: 23913142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
    Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel immunoconjugates comprised of streptonigrin and 17-amino-geldanamycin attached via a dipeptide-p-aminobenzyl-amine linker system.
    Burke PJ; Toki BE; Meyer DW; Miyamoto JB; Kissler KM; Anderson M; Senter PD; Jeffrey SC
    Bioorg Med Chem Lett; 2009 May; 19(10):2650-3. PubMed ID: 19386499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates.
    Frigerio M; Kyle AF
    Curr Top Med Chem; 2017; 17(32):3393-3424. PubMed ID: 29357801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural products as exquisitely potent cytotoxic payloads for antibody- drug conjugates.
    Gromek SM; Balunas MJ
    Curr Top Med Chem; 2015; 14(24):2822-34. PubMed ID: 25487009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
    Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
    Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive review on the elaboration of payloads derived from natural products for antibody-drug conjugates.
    Lu N; Wu J; Tian M; Zhang S; Li Z; Shi L
    Eur J Med Chem; 2024 Mar; 268():116233. PubMed ID: 38408390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Chemical Approaches for Site-Specific Conjugation of Native Antibodies: Technologies toward Next-Generation Antibody-Drug Conjugates.
    Yamada K; Ito Y
    Chembiochem; 2019 Nov; 20(21):2729-2737. PubMed ID: 30973187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates for the treatment of cancer.
    Flygare JA; Pillow TH; Aristoff P
    Chem Biol Drug Des; 2013 Jan; 81(1):113-21. PubMed ID: 23253133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.
    Harper J; Mao S; Strout P; Kamal A
    Methods Mol Biol; 2013; 1045():41-9. PubMed ID: 23913140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.